Gynaecological - oncology - SA Health Approved Cancer Chemotherapy Protocol Register

Cervical

Cervical
Protocol Administration at chemotherapy unit level Review Date
Cervical advanced cARBOplatin, PACLitaxel and bevacizumab Medium February 2025
Cervical advanced ciSplatin, PACLitaxel and bevacizumab Medium February 2025
Cervical locally advanced squamous cell carcinoma cISplatin chemoradiation Medium February 2023
Cervical recurrent or metastatic cARBOplatin and PACLItaxel Medium February 2023

Endometrial

Endometrial
Protocol Administration at chemotherapy unit level Review Date
Endometrial adjuvant cARBOplatin and PACLitaxel
Medium August 2021
Endometrial adjuvant cARBOplatin and PACLitaxel following chemoradiation (part 2) Medium February 2026
Endometrial adjuvant ciSplatin chemoradiation (part 1). The SA Health Cancer Drug Committee has endorsed the use of ciSplatin 40mg/m2 weekly as an alternative dose schedule for patients unable to tolerate the 50mg/m2 3-weekly dose Medium February 2026
Endometrial recurrent medroxyprogesterone acetate Low February 2025
Endometrial recurrent or metastatic AP (DOXOrubicin cISplatin) Medium February 2023
Endometrial recurrent or metastatic cARBOplatin and PACLItaxel Medium February 2023
Soft tissue sarcoma metastatic DOCEtaxel and gemcitabine Medium February 2022

Gestational trophoblastic disease

Gestational trophoblastic disease
Protocol Administration at chemotherapy unit level Review Date
Gestational trophoblastic disease high risk EMA-CO (etoposide methotrexate daCTINomycin (actinomycin D) CYCLOPHOSPHamide vinCRISTine) High February 2023
Gestational trophoblastic disease high risk EP-EMA (etoposide ciSplatin etoposide methotrexate daCTINomycin) High February 2025
Gestational trophoblastic disease low risk methotrexate Low February 2023
Gestational trophoblastic disease very high risk EP (etoposide and ciSplatin) High February 2025

Ovarian

Ovarian
Protocol Administration at chemotherapy unit level Review Date
Advanced, metastatic or recurrent olaparib
Low February 2022
Ovarian advanced cARBOplatin and DOCEtaxel Medium February 2023
Ovarian advanced cARBOplatin and PACLItaxel three weekly Medium February 2022
Ovarian advanced cARBOplatin and PACLItaxel weekly Medium February 2022
Ovarian advanced cARBOplatin three weekly and PACLitaxel weekly Medium February 2022
Ovarian advanced cARBOplatin PACLItaxel and bevacizumab Medium. Moves to low risk after completion of cARBOplatin/PACLitaxel treatment) February 2023
Ovarian advanced combined intravenous and intraperitoneal cISplatin and PACLItaxel High February 2022
Ovarian advanced primary treatment cARBOplatin Medium February 2023
Ovarian dysgerminoma advanced or metastatic BEP (bleomycin etoposide cISplatin) Medium February 2023
Ovarian high risk stage 1 adjuvant cARBOplatin and PACLItaxel Medium February 2023
Ovarian recurrent cARBOplatin Medium February 2023
Ovarian recurrent cARBOplatin and DOXOrubicin pegylated liposomal Medium February 2023
Ovarian recurrent cARBOplatin and gemcitabine (day 1 cARBOplatin) Medium - Day 1. Low - Day 8 February 2023
Ovarian recurrent DOXOrubicin pegylated liposomal Medium February 2023
Ovarian recurrent gemcitabine Low February 2023
Ovarian recurrent PACLItaxel weekly Medium February 2023
Ovarian recurrent topotecan (modified) three weekly Medium February 2023

Vulval

Vulval
Protocol Administration at chemotherapy unit level Review Date
Vulval advanced cISplatin chemoradiation Medium February 2023

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.